Press releases

9 June 2026 at 08:00

Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships

19 May 2026 at 08:00

Orexo announces positive outcome from an in-vivo study of OX390

7 May 2026 at 17:00 – Regulatory – General Meeting

Report from Orexo AB’s annual general meeting May 7 2026

28 April 2026 at 07:00 – Regulatory – Report – Q1

Orexo Q1 2026 Interim Report

21 April 2026 at 10:00

Invitation to presentation of Orexo´s Q1 2026 Interim Report

31 March 2026 at 17:30 – Regulatory

Number of shares and votes in Orexo

30 March 2026 at 12:00 – General Meeting

Notice of Annual General Meeting of Orexo

27 March 2026 at 10:00 – Regulatory – Report

Orexo publishes Annual Report for 2025

24 March 2026 at 07:30

Orexo R&D Day - Building global leadership in amorphous drug delivery

6 March 2026 at 10:00

Invitation & Agenda: Orexo R&D Day on March 24

6 March 2026 at 08:00

Orexo changes the organizational structure and management team to increase focus on development of new products

4 March 2026 at 08:00

Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028

19 February 2026 at 17:30 – Regulatory

Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs

5 February 2026 at 07:00 – Regulatory – Report – Q4

Orexo Interim Report Q4 2025, incl. Full Year Report

4 February 2026 at 09:30

Save the date: Orexo to host R&D Day on March 24

23 January 2026 at 10:30

Orexo invites to a presentation of the Full Year Report 2025

31 December 2025 at 17:00

Orexo closes transaction with Dexcel Pharma USA acquiring full rights to Zubsolv in the US

22 December 2025 at 21:00 – Regulatory

Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv

5 December 2025 at 09:00

Designing a rescue medication for adulterated opioids: OX390 program and BARDA partnership

23 October 2025 at 08:00 – Regulatory – Report – Q3

Orexo Q3 2025 Interim Report

17 October 2025 at 08:00 – Regulatory

Orexo´s Nomination Committee for the Annual General Meeting 2026

15 October 2025 at 09:00

Invitation to presentation of Orexo´s Q3 2025 Interim Report

1 October 2025 at 07:30

Orexo strengthens innovation and research with move to new premises

29 September 2025 at 20:30 – Regulatory

Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership

8 September 2025 at 10:00

Orexo press releases